13 Result(s)
within
Brian G. Feagan
Gastroenterology
-
Article
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
Fibrostenosis of the small bowel is common in patients with Crohn’s disease. No consensus recommendations on definition, diagnosis and management in clinical practice are currently available. In this Consensus...
-
Article
Open AccessOzanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn’s Disease
Ozanimod showed efficacy and safety in the phase 2 STEPSTONE study conducted in patients with moderately to severely active Crohn’s disease.
-
Article
Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn’s Disease: Systematic Review and Meta-Analysis
Targeting interleukin-23 (IL-23) is an important therapeutic strategy for Crohn’s disease (CD).
-
Article
An Expert Consensus to Standardize Assessment of Bowel Cleansing for Clinical Trials of Bowel Preparations for Crohn’s Disease
Despite regular need for colonoscopy in patients with Crohn’s disease (CD), the efficacy and tolerability of bowel preparation (BP) agents is rarely assessed in this population. Assessing BP quality with exist...
-
Article
Existing Bowel Preparation Quality Scales Are Reliable in the Setting of Centralized Endoscopy Reading
Development of bowel preparation products has been based upon colon cleansing rating by a local endoscopist. It is unclear how bowel preparation scales perform when centrally evaluated.
-
Article
Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review
Patients treated with immune checkpoint inhibitors (ICIs) may develop ICI-associated enterocolitis, for which there is no approved treatment.
-
Article
Placebo Rates in Randomized Controlled Trials of Pouchitis Therapy
Approximately half of the patients with ulcerative colitis (UC) who undergo restorative proctocolectomy develop pouchitis within 10 years of surgery. Currently, there are no approved pouchitis treatments. It i...
-
Article
Physicians’ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn’s Disease
Aminosalicylates are the most commonly prescribed therapy in Crohn’s disease (CD), despite uncertainty in the evidence to support their efficacy.
-
Article
Open AccessEffects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
Approximately 15–20% of ulcerative colitis patients and 20–40% of those with Crohn’s disease experience extraintestinal manifestations (EIMs) of their inflammatory bowel disease (IBD). Clinicians who treat IBD...
-
Article
An Overview of Magnetic Resonance Enterography for Crohn’s Disease
Magnetic resonance enterography (MRE) is a relatively new imaging modality that has shown promise for diagnosing, staging, and monitoring Crohn’s disease (CD) and its complications while avoiding exposure to i...
-
Article
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Current State and Future Perspectives
Current available anti-inflammatory drugs, in particular monoclonal antibodies directed against the cytokine tumor necrosis factor α (TNF), have greatly enhanced the treatment of inflammatory bowel diseases (I...
-
Chapter
Pharmacoeconomics and inflammatory bowel disease
Over the past decade preliminary data regarding the pharmacoeconomics of inflammmatory bowel disease have emerged. The synthesis of this information has culminated in the first models which evaluate the margin...
-
Article
High-Level Serum Antibodies to Bacterial Antigens Are Associated with Antibiotic-Induced Clinical Remission in Crohn's Disease: A Pilot Study
In Crohn's disease, antibiotics are used with variable efficacy, suggesting that some patients are more likely to respond. The aim of this study was to determine whether Crohn's patients with predominant serum...
